Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

Mansour, Ahmad M.; Mackensen, Friederike; Arévalo, J. Fernando; Ziemssen, Focke; Mahendradas, Padmamalini; Sibai, Abla Mehio; Hrisomalos, Nicholas F.; Lai, Timothy Y. Y.; Dodwell, David G.; Chan, Wai Man; Neß, Thomas; Banker, Alay; Pai, Sivakami A; Berrocal, María H.; Tohme, Rania A.; Heiligenhaus, Arnd; Bashshur, Ziad F.; Khairallah, Moncef; Salem, Khalil M.; Hrisomalos, Frank N; Wood, Matthew H.; Heriot, Wilson; Adán, Alfredo; Kumar, Atul; Lim, Lyndell L; Hall, Anthony J.; Becker, Matthias

doi:10.1016/j.ajo.2008.05.024

Cited by 71 publications

(59 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with subfoveal CNV were randomised to observation (113) or surgical (112) groups. 18 At 24 months, the median BCVA were 6/75 and 6/48, Eye respectively; however, this was not statistically significant. The greatest benefit was achieved with those eyes with a baseline VA of worse than 20/100.…”

Section: Surgerymentioning

confidence: 80%

Treating peripapillary choroidal neovascular membranes: a review of the evidence

Jutley

Tah

Lindfield

et al. 2011

Eye

View full text Add to dashboard Cite

Peripapillary choroidal neovascular membranes (PCNM) are defined as a collection of new choroidal blood vessels, any portion of which lies within one disc diameter of the nerve head. There are two types of PCNM, and correct pre-interventional identification of growth site has been shown to stratify the chance of visual improvement following therapy. Clinical manifestations occur only where the membrane extends over the macula, if the vessels haemorrhage into the subretinal space or fluid exudation occurs within the macula. This review provides an update and overview on the diverse range of current treatment studies and strategies being used in present clinical ophthalmic practice.

show abstract

Section: Surgerymentioning

confidence: 80%

Treating peripapillary choroidal neovascular membranes: a review of the evidence

Jutley

Tah

Lindfield

et al. 2011

Eye

View full text Add to dashboard Cite

show abstract

“…80 We pooled data from three studies that successfully treated a total of 52 ICNV eyes with bevacizumab. 30,71,73 Overall, visual acuity changed from an initial mean value of 0.8 logMAR to 0.33 logMAR at the end of a mean 5.1 months follow-up. One study 71 used three monthly injections in nine eyes, and the other two used a prn regimen.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

“…69 Anti-VEGF agents Seven studies have reported on the use of anti-VEGF therapy for CNV that is secondary to inflammation (Table 4). [70][71][72][73][74][75][76] Data pooled from these studies are derived from the treatment of 110 eyes. Although the inflammatory disease process varies between diseases, a sub-analysis reveals that the visual outcomes for the treatment of naïve eyes (mean gain of 0.28 logMAR) is better than for earlier treated eyes (0.25 logMAR).…”

Section: Anti-inflammatory and Immunosuppressive Agentsmentioning

confidence: 99%

“…In most studies, inflammatory CNV responded favourably after a single dose of bevacizumab, especially in the treatment of naïve eyes. With few exceptions, 71,73 most studies have used prn regimens for treating CNV. Both prn and monthly injection for first 3 months schedules have shown favourable outcomes.…”

Section: Anti-inflammatory and Immunosuppressive Agentsmentioning

confidence: 99%

“…One study 71 used three monthly injections in nine eyes, and the other two used a prn regimen. 30,73 Most cases respond favourably within 1 month and required a mean of 1.55 injections per eye (range: 1.4-1.7). Though the average follow-up was short, no injection-related, long-term complications were reported.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

See 2 more Smart Citations

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

CERHR bisphenol A: review and commentaries

Daston¹

2008

Birth Defects Research Pt B

View full text Add to dashboard Cite

Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

Cited by 71 publications

References 30 publications

Treating peripapillary choroidal neovascular membranes: a review of the evidence

Treating peripapillary choroidal neovascular membranes: a review of the evidence

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

CERHR bisphenol A: review and commentaries

Contact Info

Product

Resources

About